跳到正文
原文
MedPage Today·· 10 天前精选AI 评分70

严格血压控制在中风幸存者中获益,但在糖尿病患者中无显著效果

Intensive Blood Pressure Control Gets a Win in Stroke Survivors

AI 导读

两项在巴西进行的研究分别在中风幸存者和糖尿病患者中评估了严格血压控制的效果。在中风幸存者中,严格控制血压至120 mm Hg以下显著降低了主要心血管不良事件的风险,而在糖尿病患者中未观察到显著益处。

推荐理由

两项大型研究在不同患者群体中评估了严格血压控制的效果,结果显示在中风幸存者中有效,但在糖尿病患者中无显著益处。

正文

— But no significant benefit of a systolic BP target below 120 mm Hg observed in diabetes trial

by Susan Jeffrey, Contributing Writer, MedPage Today

November 9, 2026 • 5 min read

Two large trials conducted in Brazil in different patient populations came to somewhat divergent conclusions on the cardiovascular benefits of intensive blood pressure (BP) lowering.

Over roughly 4 years of median follow-up, intensive treatment targeting a systolic BP below 120 mm Hg in patients with a previous stroke or transient ischemic attack (TIA) significantly reduced the risk of major adverse cardiovascular events compared with treatment targeting a BP below 140 mm Hg (10.9% vs 13.5%, P=0.007), reported Otavio Berwanger, MD, PhD, of Imperial College London, at the American Heart Association (AHA) annual meeting in Chicago.

"We had one price to pay here that offset the benefits," he said, noting a potential increase in the composite renal endpoint, primarily driven by a sustained drop in renal function, making it likely that this was a hemodynamic effect. There was no increase in the more serious renal endpoints of renal mortality, end-stage renal disease, or need for dialysis.

Conversely, in a trial of patients with type 2 diabetes and high cardiovascular risk also reported by Berwanger, there was no effect of the same intensive BP lowering strategy over a similar timeframe on the same primary endpoint -- a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina or heart failure -- with an incidence of 6% versus 6.7% with the standard systolic BP target of below 140 mm Hg (P=0.20).

The results of the studies -- OPTIMAL-STROKE and OPTIMAL-DIABETES -- were published simultaneously in the New England Journal of Medicine.

Commenting on the results of the stroke trial, Cheryl Bushnell, MD, of Wake Forest University in Winston-Salem, North Carolina, called this a landmark trial, and applauded what the researchers were able to accomplish in terms of intensive BP lowering in this population.

"A lot of times when patients are discharged from the hospital, they have carotid stenosis, and middle cerebral artery stenosis, and everybody's nervous about lowering their blood pressure too much," she said. "So this kind of abolishes some of the concerns that a lot of neurologists and primary care physicians have had about cerebral perfusion."

Current guidelines recommend a target BP of 130/80 mm Hg in this population, Bushnell noted, but OPTIMAL-STROKE now suggests that shooting for a target systolic BP of below 120 mm Hg can improve outcomes. "We know what we need to do, but it's not the what, it's the how," she said. "Managing blood pressure in stroke patients is incredibly difficult, and somebody has to own that as a clinician."

AHA discussant Daichi Shimbo, MD, from Columbia University Irving Medical Center in New York City, agreed that implementation of these findings will be a challenge.

"If you look at these data, it's likely that a substantial portion of individuals did not achieve a systolic blood pressure less than 120 in the intensive arm," Shimbo said. "What I conclude from this is, even in a beautifully conducted trial, it is really hard to get systolic blood pressure less than 120, and I would argue, it's probably even more difficult to do it in clinical practice. So, my takeaway point is, if a target systolic blood pressure less than 120 is recommended in a future guideline, which I suspect it will be, guidance should be provided in how best to achieve this target in clinical practice."

He also pointed to the renal outcomes, noting that the number needed to treat suggested that for every 1,000 patients treated intensively for about 4 years, 26 will benefit and 17 will be harmed. "So the question I have is, will clinicians feel comfortable with this risk-benefit ratio? Of course, the benefit is [major adverse cardiovascular events] reduction, and the risk is just a creatinine bump, but one wonders what clinicians will feel about this trial."

On the other hand, Berwanger noted, the results of the diabetes trial "should be interpreted as a neutral trial, of course, but it's not the only trial."

In a pre-specified meta-analysis of these findings with previous trials looking at the same question (BPROAD, conducted in China, and ACCORD BP in North America), "there was a 16% relative reduction in the risk of major cardiovascular events," he said. "What this is saying is that potentially, there is a reduction in cardiovascular events in this population, but it's attenuated."

"No trial in isolation will be able to detect a reduction of between 10% and 15%, more or less," Berwanger added, "so you need to consider the totality of the evidence."

AHA commenter Shawna Nesbitt, MD, from the University of Texas Southwestern Medical Center in Dallas, pointed out that in previous trials, including BPROAD, women had less significant BP reduction compared with men. The larger population of women in this trial (62%), "may have skewed the trial a little bit to having a little less significance earlier on," Nesbitt said. "My opinion would be that if you follow them out longer, you more than likely see the same results."

"I think it very strongly suggests that this trial supports, rather than refutes, what we already have seen in other trials of treating hypertension more aggressively in patients with diabetes," she added.

OPTIMAL-STROKE was a multicenter, open-label trial carried out at 30 sites in Brazil. A total of 4,368 patients with elevated BP and previous ischemic stroke or TIA were randomly assigned 1:1 to receive intensive treatment with a target systolic BP of less than 120 mm Hg or standard treatment with a target of less than 140 mm Hg.

After randomization, investigators adjusted antihypertensive therapy according to treatment assignment and prespecified algorithms. Additional monthly visits were arranged as needed in the intensive-treatment group to achieve the target BP, according to the study investigators.

During follow-up, excluding the first 3 months, the mean systolic BP was 122.0 mm Hg in the intensive group and 135.2 mm Hg in the standard group.

The composite renal outcome -- sustained reduction of ≥50% in estimated glomerular filtration rate or progression to end-stage renal disease -- occurred in 3.9% of patients in the intensive-therapy group and 2.2% of patients in the standard group (HR 1.76, 95% CI 1.24-2.50). The overall incidence of serious adverse events was similar between groups, with rates of 15.1% and 15.3%, respectively.

OPTIMAL-DIABETES, an open-label trial also conducted in Brazil, included 9,476 patients with elevated BP, type 2 diabetes, and high cardiovascular risk. They were randomly assigned in a 1:1 ratio to either the intensive strategy or the standard treatment strategy.

The mean systolic BP during follow-up, again excluding the first 3 months, was 121.8 mm Hg in the intensive group and 135.4 mm Hg with standard therapy. Serious adverse events occurred in 14.9% of patients with intensive therapy and 14.6% of patients with standard therapy.

来源:MedPage Today · medpagetoday.com